Coherus BioSciences, Inc. - Common Stock (CHRS)
Frequently Asked Questions About Coherus BioSciences, Inc. - Common Stock (CHRS)
How does Coherus BioSciences approach regulatory compliance?
Coherus BioSciences is committed to maintaining the highest standards of regulatory compliance by closely adhering to guidelines set forth by the FDA and other regulatory bodies. This approach ensures the safety and efficacy of their products throughout the development process.
How does Coherus BioSciences contribute to accessibility in medicine?
Coherus BioSciences contributes to accessibility in medicine by developing biosimilars that are more affordable alternatives to branded biologics. This approach can increase patient access to high-quality therapies while reducing overall healthcare costs.
How does Coherus BioSciences ensure product quality?
Coherus BioSciences ensures product quality through rigorous development processes, adhering to stringent regulatory standards, and conducting extensive clinical testing to verify the safety, efficacy, and quality of its biosimilar products.
How many employees does Coherus BioSciences have?
As of the latest reports, Coherus BioSciences employs a diverse team of around 300 professionals, including scientists, regulatory experts, and commercial leaders, all dedicated to advancing the company's mission and product development.
Is Coherus BioSciences publicly traded?
Yes, Coherus BioSciences is publicly traded on the Nasdaq stock exchange under the ticker symbol CHRS. The company has been listed since 2014, allowing investors to buy shares in its growth and developments.
What are the key therapeutic areas of Coherus BioSciences?
Coherus BioSciences primarily focuses on therapeutic areas such as oncology and immunology. Through its biosimilars and novel biologic therapies, the company aims to address significant unmet medical needs in these fields.
What does Coherus BioSciences, Inc. do?
Coherus BioSciences, Inc. is a biotechnology company that focuses on the development and commercialization of innovative therapeutics to treat cancer and other serious diseases. Their key products include biosimilars, which are biologic medical products highly similar to already approved reference products.
What is a biosimilar?
A biosimilar is a biologic medical product that is highly similar to an already approved reference product. Biosimilars must demonstrate no clinically meaningful differences in terms of efficacy and safety, thus offering more treatment options at competitive prices.
What is CIMERLI?
CIMERLI (adalimumab-bwll) is Coherus BioSciences' biosimilar to Humira, indicated for various autoimmune conditions such as rheumatoid arthritis and Crohn's disease. It was approved by the FDA and aims to provide patients with a more cost-effective treatment option.
What is the future outlook for Coherus BioSciences?
The future outlook for Coherus BioSciences is promising, as the demand for biosimilars continues to grow. The company is focused on expanding its portfolio and progressing its clinical programs to meet the evolving needs of patients and healthcare providers.
What is the mission of Coherus BioSciences?
The mission of Coherus BioSciences is to provide patients with access to high-quality, clinically effective biosimilars and other biologic therapies at lower costs, thereby improving patient outcomes and expanding treatment options.
What partnerships or collaborations does Coherus BioSciences have?
Coherus BioSciences has formed strategic partnerships with various organizations in the biotechnology and pharmaceutical sectors. These collaborations are aimed at enhancing its capabilities in product development and expanding market access for its biosimilars.
What products does Coherus BioSciences offer?
Coherus BioSciences offers a number of biosimilars, including its flagship product, CIMERLI (adalimumab-bwll), a biosimilar to Humira, approved for the treatment of several autoimmune conditions, as well as the oncology treatment YUSIMRY (pegfilgrastim-cbgh), a biosimilar to Neulasta.
What recent developments has Coherus BioSciences made?
Recently, Coherus BioSciences has made significant strides with the approval of its biosimilars and ongoing clinical trials for its novel therapies. The company continues to work on expanding its product offerings in response to market needs.
What role does research and development play in Coherus BioSciences?
Research and development (R&D) plays a crucial role at Coherus BioSciences. The company invests heavily in R&D to drive innovation and develop effective biosimilars and novel therapeutics, thus positioning itself at the forefront of biotechnology.
When was Coherus BioSciences founded?
Coherus BioSciences was founded in 2010. Since its inception, the company has focused on advancing its portfolio of innovative therapeutics, particularly in the area of immuno-oncology.
Where is Coherus BioSciences headquartered?
Coherus BioSciences is headquartered in San Francisco, California. The company's location in this biotech hub provides access to various resources and collaboration opportunities.
Who are the competitors of Coherus BioSciences?
Coherus BioSciences faces competition from several other biotechnology firms that are also involved in the development of biosimilars and novel therapeutics, including companies like Amgen, Mylan, Pfizer, and AbbVie.
What is the current price of Coherus BioSciences, Inc. - Common Stock?
The current price of Coherus BioSciences, Inc. - Common Stock is 0.9103
When was Coherus BioSciences, Inc. - Common Stock last traded?
The last trade of Coherus BioSciences, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Coherus BioSciences, Inc. - Common Stock?
The market capitalization of Coherus BioSciences, Inc. - Common Stock is 104.88M
How many shares of Coherus BioSciences, Inc. - Common Stock are outstanding?
Coherus BioSciences, Inc. - Common Stock has 115.21M shares outstanding.